Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: J Mol Med (Berl). 2011 Aug 28;90(1):31–43. doi: 10.1007/s00109-011-0804-9

Fig. 7.

Fig. 7

pFOXi correct the increased CPT1 expression and decreased PDH activity in RVH. a–f The protein expression of CPT1 is increased in PAB RVs, whereas CPT2 remains unchanged. Trimetazidine, but not ranolazine, decreases both CPT1 and CPT2 (upper membrane in d is identical to the one shown in Fig. 6k, but has been reprobed with CPT1 antibody). g, h Representative and mean data showing decreased RV PDH activity in RVH and restoration of PDH activity by long-term pFOXi therapy